CALGARY, AB / ACCESSWIRE / June 16, 2020 / Lithium Chile Inc. ("Lithium Chile" or the "Company") is pleased to announce it has signed a Letter of Intent (LOI) with Summit Nanotech Corporation for the advancement of their green lithium extraction technology in Chile. Summit Nanotech has developed a patent pending extraction process that allows for the rapid production of lithium from natural brine sources. Its technology is state of the art and shows great promise for the economical production of lithium while significantly reducing the overall environmental impact of lithium mining. The collaboration will set new standards for responsible lithium production, which is growing more important given the global rise in demand for lithium ion batteries for renewable energy and electric vehicles.

The agreement will make Lithium Chile the preferred industry partner for the production of lithium from any discoveries related to its Chilean prospects. Summit Nanotech will be the preferred extraction technology provider on all of Lithium Chile's lithium prospects. While the agreement is non-exclusive the intention is to work together to develop Lithium Chile's prospective lithium properties and field trial Summit Nanotech's extraction process.

"This will be the inaugural field test for our DenaLi 1.0 DLE process and is an important step in proving the technology on the path to commercialization," said Amanda Hall, CEO and Founder of Summit Nanotech. "We are thrilled to be piloting our technology with Lithium Chile. Their broad expertise in exploration, consistency in governance and strong relationships within Chile – especially with respect to indigenous communities – is crucial for the sustainable development of these assets." Hall, recognized as a leading innovator in her field, is a finalist in Canada's Women in Cleantech Challenge, run by MaRS in collaboration with Natural Resources Canada.

"Over the last 2 years we have looked at a number of emerging technologies for the economical and green extraction of lithium at the well head. I truly believe the future of lithium production from brines will be technology driven and Summit's technology is one of the most exciting emerging processes we have seen," commented Steve Cochrane, President and CEO of Lithium Chile.

Together, Summit Nanotech and Lithium Chile have been chosen as part of a consortium in the final stages of a USD $4-million grant proposal to the Chilean Government Agency, CORFO.

About Lithium Chile

Lithium Chile is advancing a lithium property portfolio consisting of 110,280 hectares covering sections of 11 salars and two laguna complexes in Chile.

Lithium Chile also owns a property portfolio that is prospective for gold, silver and copper and lie within the main Chilean mega porphyry copper-gold belt. Included is the Carmona property which where an exploration program is planned shortly.

Lithium Chile's common shares are listed on the TSX-V under the symbol "LITH" and on the OTC-QB under the symbol "LTMCF".

About Summit Nanotech

Summit Nanotech is a Calgary-based cleantech company which uses nanoscience to directly extract lithium from brine sustainably. Its proprietary DenaLi 1.0 DLE process is scalable, requires no fresh water, doubles yield and reduces the use of chemicals and production of waste by 90% while rapidly producing high-purity lithium products. The company is on National Angel Capital Organization's Top 30 Most Promising Startups list and has won awards at Energy New Ventures and Inventures. For more information contact Amanda Hall, CEO and Founder, amanda@summitnanotech.com or visit www.summitnanotech.ca.

To find out more about Lithium Chile Inc., please contact Steven Cochrane, President and CEO via email: steve@lithiumchile.ca or alternately, Jeremy Ross, VP Business Development, at (604) 537-7556 or via email: jeremy@lithiumchile.ca. Lithium Chile's Chilean contact is Terry Walker, VP Exploration at (011) 562 2455-6473 or via email: twalker@chilelithium.cl.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

NOT FOR RELEASE IN THE UNITED STATES OF AMERICA

Forward Looking Statements

This news release may contain certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively "forward-looking statements"). Generally, forward-looking information can be identified by the use of forward-looking terminology such as "expects", "believes", "aims to", "plans to" or "intends to" or variations of such words and phrases or statements that certain actions, events or results "will" occur. In particular, this news release contains forward-looking statements relating to, among other things, expectations related to the LOI with Summit Nanotech.

You are cautioned that the following list of material factors and assumptions is not exhaustive. Specific material factors and assumptions include, but are not limited to: the general stability of the economic and political environment in which the Company operates; the timely receipt of required regulatory approvals; the ability of the Company to obtain future financing on acceptable terms; currency, exchange and interest rates; operating costs; the success the Company will have in exploring its prospects and the results from such prospects. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements herein, except as required by applicable securities laws. All forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

SOURCE: Lithium Chile Inc.

ReleaseID: 594026

NORTH YORK, ON / ACCESSWIRE / June 16, 2020 / ZTEST Electronics Inc. ("ZTEST" or the "Company") (CSE:ZTE) is pleased to announce that, further to the Company's Press Release of April 9, 2020, Conversance Inc., a Waterloo Ont. based private company in which ZTEST owns a 25.29 % equity interest, has successfully completed initial internal testing of Chronicle, Conversance's proprietary distributed ledger platform being built for scalability, low power consumption and intermittent connectivity.

Conversance was created in 2016 by Joseph C. Chen, for the purpose of creating a proprietary distributed ledger platform utilizing AI technologies. The primary focus of Chronicle is to store and share data in a platform that can be unequivocally trusted.

During internal testing, completed on a 256-node test network, simulating nodes distributed around the world, achieved 45,000 transactions per second (tps), with a 16.9 second latency, at 250 bytes per transaction. When the network model simulated a local network, Chronicle achieved 251,000 transactions per second (tps) at a 2.2 second latency.

Mr Chen commented "Chronicle was built from day one to enable distributed ledger applications with high levels of performance, without giving up network decentralization. Chronicle provides parallel asynchronous transaction processing in a fabric using a dynamic sharding approach. The above noted transaction rates are approximately three orders of magnitude (1000 times faster) than other commercial first generation blockchains."

Mr. Chen has a deep background in information theory, digital signal processing, and software and hardware architectures ranging from embedded to datacenter scale. He also made key contributions to the creation and popularization of smartphones. Mr. Chen has long been a resolute advocate for a digital world where personal privacy and rights can be guaranteed, despite encroachment by national and business interests who seek to mine and use private, personal information.

Conversance is continuing internal testing and design tuning of Chronicle. Additional testing results, and details of the architecture, will be made available through the Conversance website, when available.

For more information contact:

Steve Smith, CEO
(604) 837-3751
email: stevesmith15@shaw.ca

The CSE has neither approved nor disapproved the contents of this press release. The CSE does not accept responsibility for the adequacy or accuracy of this press release.

FORWARD LOOKING STATEMENTS: This press release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR in Canada (available at www.sedar.com).

SOURCE: ZTEST Electronics Inc.

ReleaseID: 594022

VANCOUVER, BC / ACCESSWIRE / June 16, 2020 / Black Tusk Resources Inc. ("Black Tusk" or the "Company) (CSE:TUSK)(OTC PINK:BTKRF)(FRA:0NB) is pleased to announce that the Company has contracted Abitibi Geophysics in Val d'Or, Quebec to undertake their OreVision 3D Induced Polarization Survey (IP) on the McKenzie East gold property located north of Val d'Or. The survey is designed to use the most advanced geophysical applications to produce high resolution results through the overburden on the property.

The IP survey will be located within the northwest area of the McKenzie East Gold Property in order to trace possible gold-bearing structures extending eastward from the Monarch Gold- McKenzie Break Property. The cut-line grid is to be prepared within the coming week. The results of the IP survey will be combined with the results of MMI processing of soil samples taken in the last month in order to locate the best targets for diamond drilling.

In late May, the Company's contractor VD Géo Service completed the acquisition of 205 soil samples along pre-existing access routes and other areas that were amenable to sampling. The samples were submitted to SGS Mineral Labs for analysis. Results of analysis are expected within the coming weeks.

The Company has acquired a permit that allows for the construction of 18 drill pads with supporting water supply stations and access trails. Black Tusk plans to conduct this upcoming drill program in the Summer 2020 exploration season, following the completion of ground surveys.

‘'We are extremely excited to conduct 3D IP Surveying on the McKenzie East Gold Project- this advanced technology will help us define high-priority drill targets for this Summer's anticipated Drill Program.'' said CEO, Richard Penn.

The Company also announces that Alexander Tarasov has resigned from the Board of Directors. The Company thanks Mr. Tarasov for his tremendous service to the Company and wish him every success in the future.

The Company also advises that it has settled outstanding indebtedness of $31,500 in exchange for common shares at a price of $0.065 per share. The shares are subject to a four month hold period expiring four months from the date of issue.

Perry Grunenberg, PGeo, a "Qualified Person" as that term is defined under NI 43-101, has reviewed and approved the technical information contained in this news release. Mr. Grunenberg is also a director of the Company.

About Black Tusk Resources Inc.

Black Tusk Resources is a gold-focused Canadian exploration company with operations primarily based in the world-class Abitibi greenstone belt region of Quebec. Black Tusk currently holds 100-per-cent ownership in five separate gold and palladium projects in Canada.

On behalf of the Board of Directors

Richard Penn
CEO
(778) 384-8923

Cautionary Statement

This press release contains forward-looking statements based on assumptions as of that date. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to exploration and development; the ability of the Company to obtain additional financing; the Company's limited operating history; the need to comply with environmental and governmental regulations; fluctuations in the prices of commodities; operating hazards and risks; competition and other risks and uncertainties, including those described in the Company's Prospectus dated September 8, 2017 available on www.sedar.com. Accordingly, actual and future events, conditions, and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

SOURCE: Black Tusk Resources Inc

ReleaseID: 594008

EASTPOINTE, MI / ACCESSWIRE / June 16, 2020 / Resgreen Group (OTC PINK:RGGI) Resgreen Group (RGGI), a leading mobile robot company, is pleased to announce that its CEO Parsh Patel and Director Brian Kistler will cancel a total of 12 million shares of common stock of the fast-growing company.

CEO Parsh Patel and Director Brian Kistler have instructed RGGI's transfer agent to cancel six million shares each and return them to the company's treasury effective immediately.

"I am deeply committed to the vision of our company and our plan of action to grow as the premier provider of automation solutions," said Parsh Patel, CEO of RGGI. "My goal in cancelling my own six million shares is to show the investment community my enthusiasm and dedication for where we are headed as a company in the rapidly growing automation industry where there are endless opportunities to help companies increase flexibility, reduce downtime and improve bottom lines."

RGGI recently announced its commitment to developing an autonomous mobile robot (AMR) equipped with ultraviolet-C (UVC) light for disinfecting facilities and a corresponding human presence sensor to ensure the vehicle's safe operation. The Eastpointe, Michigan-based company also offers a variety of automation consulting services.

About Resgreen Group International, Inc. (RGGI)

RGGI is a leading developer of Artificial Intelligence Robotics (AIRs), Autonomous Mobile Robots (AMRs), and Automatic Guided Vehicles (AGVs). RGGI's highly skilled engineers have years of experience in the material handling and robotics industries, which has led to significant intellectual property for the company.

RGGI also provides consulting services including backend operational oversight, material handling assessment, work-flow analysis, and steady state yield management using artificial intelligence, technology and management systems. For more information visit http://resgreenint.com.

Contact: Sarah Carlson
scarlson@companystorytellers.com
248.755.7680 cell

SOURCE: Resgreen Group International Inc

ReleaseID: 594003

$0.0062 per share to be paid on or about June 30, 2020

LAS VEGAS, NV / ACCESSWIRE / June 16, 2020 / CBA Florida, Inc. (www.cbafloridainc.com) (OTC PINK:CBAI) ("CBAI" or the "Company") today announced that its Board of Directors (the "Board") has approved an initial liquidating cash distribution of $0.0062 per share. The distribution will be paid on or about June 30, 2020. The Board has fixed the close of business on June 26, 2020 as the record date for determining shareholders entitled to receive the initial liquidating distribution. The Company intends to file articles of dissolution with the Florida Department of State Division of Corporations on June 26, 2020, the record date for the initial liquidating distribution. In connection with the effectiveness of the articles of dissolution, CBAI will close its stock transfer books and discontinue recording transfers of common stock, effective as of 5:00 p.m. Eastern Time on June 26, 2020. As a result, the common stock, and stock certificates evidencing the shares of common stock, will no longer be assignable or transferable on the Company's books, other than transfers by will, intestate succession or operation of law.

Subject to uncertainties inherent in the winding up of the Company, CBAI may make one or more additional liquidating distributions. However, no assurances can be made as to the ultimate amounts to be distributed, if any, or the timing of any such distributions.

David Sandberg, CBAI's Chairman, stated, "After what has been a long and active process since the Company's largest shareholder, Red Oak Partners, LLC ("Red Oak"), invested in the Company in April 2015, the Board is pleased to approve an initial liquidating distribution to shareholders. At the time of Red Oak's investment into the Company five years ago, the Company was in a tenuous leverage position post litigation, a competitor was seeking to take over the Company, EBITDA was set to decline dramatically as customers discontinued orders for what was then a profitable tissue business, and the core cord blood processing and storage business was in near run-off with minimal new customer growth. Facing the prospects of negative EBITDA and cash flow, the Board quickly reduced operating costs including the outsourcing of all lab and storage functions for new customers and initiated a process to monetize assets in order to maximize shareholder value. While we attempted to sell the company via a stock purchase deal, the best value for shareholders came from the sale of substantially all of the Company's assets, which we closed on over two years ago. Subsequent to the close of the asset sale, the Board attempted to sell the remaining shell of the Company with its cash (and minimal usable net operating losses), but we were unable to execute a transaction that provided more value to shareholders than a liquidation and dissolution process. Accordingly, we intend to file articles of dissolution, substantially in the form as were recently approved by our shareholders. I would personally like to thank Anthony Snow for his work as President of CBAI, and to thank our Board, employees, and advisors for their hard work that has enabled this positive outcome for shareholders. This initial per-share liquidating distribution amount is more than triple the share price where Red Oak (and others who invested at that time) invested in the Company, and frankly represents a successful outcome for shareholders versus what we believe the outcome would have been had Red Oak not invested in the Company. Although we are hopeful that there will be additional liquidating distributions issued going forward, the Board cannot commit to this until the dissolution process has more fully run its course."

About CBA Florida, Inc.

CBA Florida, Inc., formerly Cord Blood America, Inc., does not currently have any active business operations and consists of the cash, receivables, and liabilities remaining post-closing of the sale of substantially all of the Company's assets.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements. The Company uses words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements are based largely on the Company's expectations and are subject to a number of risks and uncertainties, certain of which are beyond the Company's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its continuing limited operations, as well as liabilities and third-party claims currently existing or which may arise in the future. The Company encourages you to review other factors that may affect its future results in its filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

Investor Contact:

Anthony Snow
asnow@cbafloridainc.com

SOURCE: CBA Florida, Inc.

ReleaseID: 593981

Mr. Bouchard to contribute his solid technical and operating knowledge as a representative for Yamana Gold

MONTREAL, QC / ACCESSWIRE / June 16, 2020 / MONARCH GOLD CORPORATION ("Monarch" or the "Corporation") (TSX:MQR)(OTC PINK:MRQRF)(FRANKFURT:MR7) is pleased to announce the appointment of Yohann Bouchard as a director of the Corporation.

Mr. Bouchard is currently Senior Vice President, Operations of Yamana Gold Inc. He joined Yamana in October 2014. Mr. Bouchard has obtained progressively more technical and operating experience over a 24-year career in mining with a particular focus on underground and open pit operations. Prior to joining Yamana, Mr. Bouchard occupied key operating and technical positions with Primero Mining Corporation, IAMGOLD Corporation, Breakwater Resources Ltd. and Cambior Inc. Mr. Bouchard oversaw precious and base metal operations in both the Americas and in Africa. Mr. Bouchard holds a Bachelor of Mining Engineering degree from École Polytechnique of Montréal. He is registered as a professional engineer with Professional Engineers Ontario.

"I would like to welcome Mr. Bouchard to Monarch's Board of Directors on behalf of the Board," said Michel Bouchard, Chairman of the Board of Directors of Monarch. "His solid experience with underground and open pit operations at Yamana and other large mining companies will be of great value to us as we continue to work on developing our flagship Wasamac gold project and our other promising gold prospects, including our Beaufor underground mine and McKenzie Break project. We are very pleased to have him on board at this stage in Monarch's development."

The Board of Directors has granted a total of 100,000 stock options (individually, an "Option" and collectively, the "Options") to a director, effective June 15, 2020. The Options are granted in accordance with the terms and conditions of the Corporation's current stock option plan.

The Options vest in four equal tranches, with each Option entitling the holder to purchase one common share of the Corporation at a price of $0.275, for a period of five years starting on June 15, 2020.

ABOUT MONARCH GOLD CORPORATION

Monarch Gold Corporation (TSX:MQR) is an emerging gold mining company focused on becoming a 100,000 to 200,000 ounce per year gold producer through its large portfolio of high-quality projects in the Abitibi mining camp in Quebec, Canada. The Corporation currently owns over 315 km² of gold properties (see map), including the Wasamac deposit (measured and indicated resource of 2.6 million ounces of gold, which includes proven and probable reserves of 1.8 million ounces of gold), the Beaufor, Croinor Gold (see video), McKenzie Break and Swanson advanced projects, and the Camflo and Beacon mills. It also offers custom milling services out of its 1,600 tonne-per-day Camflo mill.

Forward-Looking Statements

The forward-looking statements in this press release involve known and unknown risks, uncertainties and other factors that may cause Monarch's actual results, performance and achievements to be materially different from the results, performance or achievements expressed or implied therein. Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this press release.

FOR MORE INFORMATION:

Jean-Marc Lacoste 1-888-994-4465
President and Chief Executive Officer
jm.lacoste@monarquesgold.com

Mathieu Séguin 1-888-994-4465
Vice President, Corporate Development
m.seguin@monarquesgold.com

Elisabeth Tremblay 1-888-994-4465
Senior Geologist – Communications Specialist
e.tremblay@monarquesgold.com
www.monarquesgold.com

SOURCE: Monarch Gold Corporation

ReleaseID: 593971

SAN DIEGO, CA / ACCESSWIRE / June 16, 2020 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Carnival Corporation & Plc (NYSE:CCL) shares.

Investors, who purchased shares of Carnival Corporation & Plc (NYSE:CCL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

On April 16, 2020, when Carnival Corporation & Plc still had at sea two (2) of its cruise ships, an article was published titled "Carnival Executives Knew They Had a Virus Problem, But Kept the Party Going." In that article, it was revealed that Carnival Corporation & Plc may have failed to adequately protect passengers from COVID-19 on a series of cruise voyages, and indeed continued to operate new cruise departures despite its knowledge that the threat posed by COVID-19 had materialized on its ships and was likely to proliferate further.

Then, on May 1, 2020, an article was published entitled "House Panel Opens Carnival Probe Over Cruise Ship Outbreaks." The article reported, in part, that "[t]he U.S. House Committee on Transportation and Infrastructure . . . opened an inquiry into Carnival Corp.'s handling of the Covid-19 outbreaks that have resulted in more than 1,500 confirmed cases of the novel coronavirus aboard its cruise ships, as well as dozens of passengers and crew deaths." The article quoted a letter to the Company from the House committee chair, Peter Fazio (D. Or.), which reportedly stated, in part, that "' We would hope that the reality of the Covid-19 pandemic will place a renewed emphasis on public health and passenger safety, but frankly that has not been seen up to this point. . . . It seems as though Carnival Corporation and its portfolio of nine cruise lines, which represents 109 cruise ships, is still trying to sell this cruise line fantasy and ignoring the public health threat.'"

The plaintiff alleges that the defendants failed to disclose to investors that the Company's medics reported increasing events of COVID-19 illness on the Company's ships, that Carnival had violated port of call regulations by concealing the amount and severity of COVID-19 infections onboard its ships, that in responding to the outbreak of COVID-19, Carnival failed to follow the Company's health and safety protocols developed in the wake of other communicable disease outbreaks, that by continuing to operate, Carnival ships were responsible for continuing to spread COVID-19 at various ports throughout the world, and that as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Those who purchased Carnival Corporation & Plc (NYSE:CCL) shares should contact the Shareholders Foundation, Inc.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

SOURCE: Shareholders Foundation, Inc.

ReleaseID: 593988

IRVINE, CA / ACCESSWIRE / June 16, 2020 / Netlist, Inc. (OTCQX:NLST) announced that the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) has affirmed the U.S. Patent Trial and Appeal Board's (PTAB) decision upholding the validity of Netlist's U.S. 7,619,912 (‘912) patent. The ruling came after last week's oral hearing before a three-judge panel at the Federal Circuit and pending an appeal granted by the Supreme Court of the U.S., the decision is final and binding on future cases.

"For ten years Netlist has steadfastly opposed Google's misguided campaign to invalidate the ‘912 patent," said Netlist's CEO, C.K. Hong. "We are very pleased that in the end the appellate court made it clear that the claims of this seminal patent are indeed valid and in so doing, further vindicate our decade-long defense of the company's strategic intellectual property. We will now move to lift the stay in the patent infringement lawsuit against Google in the U.S. District Court for the Northern District of CA., in order to recover current and past damages related to the ‘912 patent."

In response to Netlist's 2009 complaint, Google first filed its petition for reexamination of the '912 patent in 2010 and was later joined in its effort by Inphi and Smart Modular. On January 31, 2019 PTAB denied Google's request for a rehearing of the PTAB's previous decision upholding the validity of the '912 patent claims. The PTAB's extensive rehearing decision adopted Netlist's positions on the claims and rejected Google's invalidity arguments involving the specific use of rank-selecting signals for rank multiplication.

Netlist believes that the teachings of the '912 patent can be found in various DDR3 and DDR4 server DIMMs (Dual Inline Memory Module) as well as future products that will be produced under the DDR5 server DIMM standards currently being established by the industry.

About Netlist

Netlist provides high-performance SSDs and modular memory subsystems to enterprise customers in diverse industries. The Company's NVMe™ SSD portfolio provides industry-leading performance offered in multiple capacities and form factors. HybriDIMM™, Netlist's next-generation storage class memory product, addresses the growing need for real-time analytics in Big Data applications, in-memory databases, high-performance computing and advanced data storage solutions. Netlist also manufactures a line of specialty and legacy memory products to storage customers, appliance customers, system builders and cloud and datacenter customers. Netlist holds a portfolio of patents in the areas of server memory, hybrid memory, storage class memory, rank multiplication and load reduction. To learn more, visit www.netlist.com.

Safe Harbor Statement
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than historical facts and often address future events or Netlist's future performance. Forward-looking statements contained in this news release include statements about Netlist's ability to execute on its strategic initiatives. All forward-looking statements reflect management's present expectations regarding future events and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed in or implied by any forward-looking statements. These risks, uncertainties and other factors include, among others: risks related to Netlist's plans for its intellectual property, including its strategies for monetizing, licensing, expanding, and defending its patent portfolio; risks associated with patent infringement litigation initiated by Netlist, such as its ongoing proceedings against SK hynix Inc., or by others against Netlist, as well as the costs and unpredictability of any such litigation; risks associated with Netlist's product sales, including the market and demand for products sold by Netlist and its ability to successfully develop and launch new products that are attractive to the market; the success of product, joint development and licensing partnerships; the competitive landscape of Netlist's industry; and general economic, political and market conditions, including quarantines, factory slowdowns or shutdowns, and travel restrictions resulting from the COVID-19 pandemic. All forward-looking statements reflect management's present assumptions, expectations and beliefs regarding future events and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed in or implied by any forward-looking statements. These and other risks and uncertainties are described in Netlist's annual report on Form 10-K for its most recently completed fiscal year filed on March 10, 2020, and the other filings it makes with the U.S. Securities and Exchange Commission from time to time, including any subsequently filed quarterly and current reports. In light of these risks, uncertainties and other factors, these forward-looking statements should not be relied on as predictions of future events. These forward-looking statements represent Netlist's assumptions, expectations and beliefs only as of the date they are made, and except as required by law, Netlist undertakes no obligation to revise or update any forward-looking statements for any reason.

For more information, please contact:

Investors/Media
The Plunkett Group
Mike Smargiassi/Sharon Oh
NLST@theplunkettgroup.com
(212) 739-6729

SOURCE: Netlist, Inc. via EQS Newswire

ReleaseID: 594039

Lenzilumab median time to recovery of five days compares favorably to remdesivir's 10 days in a similar patient group
Lenzilumab Phase 3 potential registration study ongoing in severe and critical COVID-19 patients
Humanigen to host a webinar today at 4:30 p.m. ET to discuss results of the initial cohort of patients treated with lenzilumab

BURLINGAME, CA / ACCESSWIRE / June 16, 2020 / Humanigen, Inc., (OTCQB:HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company's proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced additional analysis on the first clinical use of lenzilumab in 12 COVID-19 patients. The manuscript, titled ‘First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia,' was published online at medRxiv.org, (https://www.medrxiv.org/content/10.1101/2020.06.08.20125369v2).

A secondary analysis was conducted by Humanigen comparing patients with similar baseline characteristics treated with lenzilumab to patients treated with remdesivir. Results of this analysis are shown in the table below. Patients treated with lenzilumab showed rapid clinical improvement with a median time to improvement of five days and a median time to recovery of five days. In comparison, patients treated with remdesivir demonstrated a median time to improvement of 10 to 11 days and median time to recovery of 10 to 11 days1. Remdesivir was granted emergency use authorization based on time to recovery of 11 days in the Adaptive COVID-19 Treatment Trial (ACTT-1)2.

Patient Baseline Characteristics; Days of Treatment

 
1 day Lenzilumab
 
5 day Remdesivir
 
10 day Remdesivir

Median age (IQR)

 
65(52-70)
 
 
61(50-69)
 
 
62(50-71)

Male (%)

 
67%
 
 
60%
 
 
68%

Race (%)

White

 
75%
 
 
71%
 
 
70%

Black

 
0%
 
 
10%
 
 
12%

Asian

 
17%
 
 
10%
 
 
13%

Other

 
8%
 
 
8%
 
 
5%

Median BMI (IQR)

 
29(24-36)
 
 
29(25-34)
 
 
29(25-33)

Comorbidities

Diabetes

 
58%
 
 
24%
 
 
22%

Hypertension

 
58%
 
 
50%
 
 
50%

Asthma

 
8%
 
 
14%
 
 
11%

Oxygenation Status

IMV

 
–
 
 
2%
 
 
5%

High-Flow or NIPPV

 
33%
 
 
24%
 
 
30%

Low-Flow

 
67%
 
 
56%
 
 
54%

Ambient Air

 
0%
 
 
17%
 
 
11%

Median days of hospitalization before first dose (IQR)

 
2(1-4)
 
 
2(1-3)
 
 
2(1-3)

Clinical Outcome Measures

Median Time to Improvement

 
5
 
 
10
 
 
11

Median Time to Recovery

 
5
 
 
10
 
 
11

Clinical Improvement Day 14

 
100%
 
 
64%
 
 
54%

The ability of lenzilumab to prevent and/or treat cytokine storm has been previously published3. The company believes a combination of lenzilumab to treat cytokine storm and a direct-acting antiviral may be synergistic in the treatment of patients with COVID-19, given the differing mechanisms of action of these two drug categories.

The results of this additional analysis have several limitations including the small initial cohort treated with lenzilumab, neither data set included a placebo arm, and the inherent problems of making cross trial comparisons. Nevertheless, this secondary analysis was conducted to provide context for the data generated to date with lenzilumab.

Company to Host Conference Call

Humanigen will host a webinar today at 4:30 p.m. ET to discuss the results of the initial cohort of patients treated with lenzilumab. All stakeholders are invited to participate in the call.

To participate on the conference call, please dial (833) 714-0938 from the U.S. or +1 (778) 560-2680 from outside the U.S. The conference ID number is 4442099. A simultaneous webcast of the call and presentation can be accessed by visiting:

https://event.on24.com/wcc/r/2430799/D1BD079E7F6B3E17A5E0A3A7ABD6EA23.

In addition, a replay of the webcast will be available on the company website for 90 days following the event.

More details on the company's programs in COVID-19 can be found on the company's website at www.humanigen.com under the COVID-19 tab, and details of the Phase III potential registration study can be found at clinicaltrials.gov using ClinicalTrials.gov Identifier NCT04351152.

About COVID-19

COVID-19 is an infectious disease caused by SARS-CoV-2. COVID-19 has become a global pandemic, with more than 8 million confirmed cases and almost 450,000 deaths reported to date. Patients with severe cases of COVID-19 experience severe viral pneumonia that can progress to acute respiratory distress syndrome (ARDS), respiratory failure and death.

In severe and critical patients with COVID-19, published research suggests GM-CSF as the key link between pathogenic Th1 cells and inflammatory monocytes, which secrete additional GM-CSF4. Lenzilumab is a late clinical-stage, monoclonal antibody targeting GM-CSF, a pro-inflammatory cytokine up-regulated in the serum of COVID-19 patients5. The percentages of certain GM-CSF-expressing cells are significantly higher in the blood of ICU-admitted COVID-19 patients compared with healthy controls and are more pronounced in ICU-admitted COVID-19 patients versus non-ICU patients4.

1. Goldman J, Lye D, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. New England Journal of Medicine. May 27, 2020. DOI: 10.1056/NEJMoa2015301

2. Beigel J, Tomashek K, et al. Remdesivir for the Treatment of Covid-19-Preliminary Report. New England Journal of Medicine. May 22, 2020. DOI: 10.1056/NEJMoa2007764

3. Sterner R, Sakemura R, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. February 14, 2019. doi: 10.1182/blood-2018-10-881722

4. Zhou Y, Fu B, Zheng X, et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. Pre-Print. 2020. https://doi.org/10.1101/2020.02.12.945576.

5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/s0140-6736(20)30183-5.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of inflammation and cancers via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection as well as the serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. The company's immediate focus is to prevent or minimize the cytokine storm that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection and also in combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company's proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A potential registrational Phase III study in COVID-19 patients is currently enrolling. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T-cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). For more information, visit www.humanigen.com.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for the Phase III study and the potential future development of lenzilumab to minimize or reduce the severity of lung dysfunction associated with severe and critical COVID-19 infections or to be approved by FDA for such use or to help CAR-T reach its full potential or to deliver benefit in preventing GvHD. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and potential need for additional capital to conduct the Phase III study and grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

CONTACT:

Media
Darcie Robinson
Westwicke, an ICR company
203-919-7905
darcie.robinson@icrinc.com

Investors
Victoria Meissner, MD
Westwicke, an ICR company
victoria.meissner@westwicke.com
646-677-1837

SOURCE: Humanigen, Inc.

ReleaseID: 594044

MURFREESBORO, TN / ACCESSWIRE / June 16, 2020 / National Health Investors, Inc. (NYSE:NHI) today provided a business update regarding its monthly contractual rent collections and average occupancy from its three largest senior housing operators.

Collections

NHI has collected 99.4% of contractual rent in June to date and collected 100% of contractual rent in May. As previously discussed in its second quarter earnings call, NHI collected 99.7% of contractual rent in April.

Occupancy

The following table summarizes the average portfolio occupancy for Bickford, Holiday and SLC for the periods indicated, excluding development properties in operation less than 24 months, notes receivable, and properties transitioned to new operators or disposed. Bickford Same-Store occupancy excludes properties that have been operated by Bickford for less than 24 months.

About NHI

Incorporated in 1991, National Health Investors, Inc. (NYSE: NHI) is a real estate investment trust specializing in sale-leaseback, joint-venture, mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments. NHI's portfolio consists of independent, assisted and memory care communities, entrance-fee retirement communities, skilled nursing facilities, medical office buildings and specialty hospitals. For more information, visit www.nhireit.com.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding the Company's, tenants', operators', borrowers' or managers' expected future financial position, results of operations, cash flows, funds from operations, dividend and dividend plans, financing opportunities and plans, capital market transactions, business strategy, budgets, projected costs, operating metrics, capital expenditures, competitive positions, acquisitions, investment opportunities, dispositions, acquisition integration, growth opportunities, expected lease income, continued qualification as a real estate investment trust ("REIT"), plans and objectives of management for future operations, continued performance improvements, ability to service and refinance our debt obligations, ability to finance growth opportunities, and similar statements including, without limitation, those containing words such as "may," "will," "believes," "anticipates," "expects," "intends," "estimates," "plans," and other similar expressions are forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Such risks and uncertainties include, among other things; the impact of COVID-19 on our tenants, borrowers, economy and the Company; the operating success of our tenants and borrowers for collection of our lease and interest income; the success of property development and construction activities, which may fail to achieve the operating results we expect; the risk that our tenants and borrowers may become subject to bankruptcy or insolvency proceedings; risks related to governmental regulations and payors, principally Medicare and Medicaid, and the effect that lower reimbursement rates would have on our tenants' and borrowers' business; the risk that the cash flows of our tenants and borrowers would be adversely affected by increased liability claims and liability insurance costs; risks related to environmental laws and the costs associated with liabilities related to hazardous substances; the risk that we may not be fully indemnified by our lessees and borrowers against future litigation; the success of our future acquisitions and investments; our ability to reinvest cash in real estate investments in a timely manner and on acceptable terms; the potential need to incur more debt in the future, which may not be available on terms acceptable to us; our ability to meet covenants related to our indebtedness which impose certain operational limitations and a breach of those covenants could materially adversely affect our financial condition and results of operations; the risk that the illiquidity of real estate investments could impede our ability to respond to adverse changes in the performance of our properties; risks associated with our investments in unconsolidated entities, including our lack of sole decision-making authority and our reliance on the financial condition of other interests; our dependence on revenues derived mainly from fixed rate investments in real estate assets, while a portion of our debt bears interest at variable rates; the risk that our assets may be subject to impairment charges; and our dependence on the ability to continue to qualify for taxation as a real estate investment trust. Many of these factors are beyond the control of the Company and its management. The Company assumes no obligation to update any of the foregoing or any other forward looking statements, except as required by law, and these statements speak only as of the date on which they are made. Investors are urged to carefully review and consider the various disclosures made by NHI in its periodic reports filed with the Securities and Exchange Commission, including the risk factors and other information disclosed in NHI's Annual Report on Form 10-K for the most recently ended fiscal year. Copies of these filings are available at no cost on the SEC's web site at https://www.sec.gov or on NHI's web site at https://www.nhireit.com.

Contact: Dana Hambly, Director, Investor Relations

Phone: (615) 890-9100

SOURCE: National Health Investors via EQS Newswire

ReleaseID: 594006